Effectiveness Associated With Pfizer/BioNTech Vaccine Against Emergency Department, Urgent Care Encounters for SARS-CoV-2 Infection Among Adolescents

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, AUGUST 3, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.25162?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080322

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The findings of this study including 3,168 adolescents suggest that two doses of the Pfizer/BioNTech COVID-19 vaccine were associated with high levels of protection against emergency department and urgent care encounters related to the Delta and Omicron variants of SARS-CoV-2 in the first few months after vaccination. However, effectiveness waned over time, especially against Omicron. A third dose of the Pfizer/BioNTech vaccine was associated with improved protection against Omicron beyond that seen initially after two doses, underscoring the importance of boosters for adolescents ages 12 to 17.

Authors: Sara Y. Tartof, Ph.D., M.P.H., of Kaiser Permanente Southern California in Pasadena, is the corresponding author.

  

(doi:10.1001/jamanetworkopen.2022.25162)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.